Literature DB >> 18475391

Septic shock and sepsis syndrome in obstetric patients.

P G Pryde1, B Gonik.   

Abstract

Septic shock is a life-threatening clinical syndrome that, despite its rare occurrence in obstetrics, remains a leading cause of maternal mortality. Its pathophysiology is explained by a profound systemic response to a complex variety of host cellular and humoral mediators elaborated after exposure to microbial toxins. Early recognition, prompt diagnostic workup, and immediate initiation of therapy improve outcomes. Therefore, recent publications have popularized the concept of the "sepsis syndrome," a preshock list of clinical criteria associated with progressive sepsis. Needed diagnostic studies should never be withheld because of "pregnancy concerns." With critically ill patients, the risk-to-benefit ratio supports the use of these diagnostic studies in almost all circumstances. Standard therapy is directed principally at restoring tissue perfusion by intravascular volume expansion and in some instances vasoactive pharmacological intervention. Simultaneously, identification of the source of infection and commencement of appropriate empiric antibiotic treatment are critical. In some cases, surgical abscess drainage or debridement of infected necrotic tissue will need to be considered. Novel approaches to treatment that attempt to reduce the systemic response to microbial toxins are promising and under active investigation. Pregnancy-specific considerations include the following: 1) initial signs or symptoms of septic shock may be masked by normal physiologic alterations of pregnancy; 2) a mixed polymicrobial group of organisms, consistent with lower genital tract flora, should be anticipated; and 3) initial therapy should be directed at maternal concerns since adverse fetal effects are most likely the result of maternal decompensation.

Entities:  

Year:  1994        PMID: 18475391      PMCID: PMC2364383          DOI: 10.1155/S1064744994000645

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  59 in total

1.  More lung cancer but better survival. Implications of secular trends in "necropsy surprise" rates.

Authors:  C K Chan; C K Wells; M J McFarlane; A R Feinstein
Journal:  Chest       Date:  1989-08       Impact factor: 9.410

2.  Effects of endotoxin on the pregnant baboon and fetus.

Authors:  H O Morishima; W H Niemann; L S James
Journal:  Am J Obstet Gynecol       Date:  1978-08-15       Impact factor: 8.661

3.  Multiple-organ-failure syndrome.

Authors:  C J Carrico; J L Meakins; J C Marshall; D Fry; R V Maier
Journal:  Arch Surg       Date:  1986-02

4.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.

Authors:  R C Bone; C J Fisher; T P Clemmer; G J Slotman; C A Metz; R A Balk
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

Review 5.  Pharmacotherapy of circulatory shock.

Authors:  T L Higgins; B Chernow
Journal:  Dis Mon       Date:  1987-06       Impact factor: 3.800

6.  Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

Authors:  J D Baumgartner; M P Glauser; J A McCutchan; E J Ziegler; G van Melle; M R Klauber; M Vogt; E Muehlen; R Luethy; R Chiolero
Journal:  Lancet       Date:  1985-07-13       Impact factor: 79.321

7.  Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis.

Authors: 
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

8.  Acquired renal insufficiency in critically ill patients.

Authors:  P I Menashe; S A Ross; J E Gottlieb
Journal:  Crit Care Med       Date:  1988-11       Impact factor: 7.598

9.  Septic shock during pregnancy.

Authors:  W Lee; S L Clark; D B Cotton; B Gonik; J Phelan; S Faro; R Giebel
Journal:  Am J Obstet Gynecol       Date:  1988-08       Impact factor: 8.661

Review 10.  Myocardial dysfunction in sepsis.

Authors:  R E Cunnion; J E Parrillo
Journal:  Crit Care Clin       Date:  1989-01       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.